Aileron Therapeutics Inc $ 1.84 -0.11 (-5.64%)
Volume:
5,644,941
Avg Vol (1m):
3,493,583
Market Cap $:
153.84 Mil
Enterprise Value $:
144.81 Mil
P/E (TTM):
0.00
P/B:
5.80
Financial Strength | 4/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 2.77 | ||
Debt-to-Equity | 0.41 | ||
Debt-to-EBITDA | -0.22 | ||
Piotroski F-Score | 2 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
ROE % | -150.47 | ||
ROA % | -90.57 | ||
ROC (Joel Greenblatt) % | -385.96 | ||
3-Year EBITDA Growth Rate | 9.6 | ||
3-Year EPS without NRI Growth Rate | 14.4 |
ALRN
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 5.8 | ||
EV-to-EBIT | -6.12 | ||
EV-to-EBITDA | -6.18 | ||
Current Ratio | 3.04 | ||
Quick Ratio | 3.04 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -23.7 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 5.75 | ||
Earnings Yield (Greenblatt) % | -16.34 |